Squarepoint
DSGN icon

Squarepoint’s Design Therapeutics DSGN Stock Holding History

Squarepoint’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$916K Buy
86,117
+39,975
+87% +$404K ﹤0.01% 2840
2025
Q4 		$433K Buy
+46,142
New +$361K ﹤0.01% 3325
2025
Q1 		– Sell
-48,186
Closed -$297K – 4770
2024
Q4 		$297K Sell
48,186
-36,945
-43% -$214K ﹤0.01% 4151
2024
Q3 		$458K Sell
85,131
-4,824
-5% -$22.7K ﹤0.01% 3167
2024
Q2 		$301K Buy
89,955
+53,518
+147% +$209K ﹤0.01% 3429
2024
Q1 		$147K Sell
36,437
-1,992
-5% -$5.32K ﹤0.01% 3711
2023
Q4 		$102K Sell
38,429
-4,133
-10% -$9.47K ﹤0.01% 3753
2023
Q3 		$100K Buy
42,562
+972
+2% +$4.53K ﹤0.01% 3556
2023
Q2 		$262K Sell
41,590
-67,624
-62% -$414K ﹤0.01% 3050
2023
Q1 		$630K Buy
+109,214
New +$817K ﹤0.01% 2168
2021
Q2 		– Sell
-23,493
Closed -$702K – 3342
2021
Q1 		$702K Buy
+23,493
New +$792K ﹤0.01% 1776

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Squarepoint's DSGN Position: Q1 2026 in Review

Squarepoint increased its Design Therapeutics (DSGN) stake by 87% in Q1 2026, buying an estimated $404K and bringing the position to 86,117 shares worth $916K. The position accounts for ﹤0.01% of the portfolio, ranked #2840.

Squarepoint first reported a position in DSGN in Q1 2021 and has held it in 11 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Squarepoint held 86,117 shares of Design Therapeutics worth $916K as of Q1 2026.
  • Squarepoint bought 39,975 Design Therapeutics shares in Q1 2026, an estimated $404K.
  • Design Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2840 holding.
  • Squarepoint first reported a position in Design Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.